Patient Characteristics and Treatment Patterns From Early Crizanlizumab Use in Real-world Setting: Preliminary Analysis From Select Sickle Cell Centers

Clinical trial NCT05833022 · COMPLETED

Trial details

NCT number: NCT05833022
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Study type: OBSERVATIONAL

Sickle Cell Disease

Start date: 2021-07-30
Primary completion: 2022-04-18
Enrollment: 297

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.